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Background: The surface of the human eye is covered by corneal epithelial cells (CECs) which regenerate from a
small population of limbal epithelial stem cells (LESCs). Cell therapy with LESCs is a non-penetrating treatment for
preventing blindness due to LESC deficiency or dysfunction. Our aim was to identify new putative molecular
markers and upstream regulators in the LESCs and associated molecular pathways.
Results: Genome-wide microarray transcriptional profiling was used to compare LESCs to differentiated human CECs.
Ingenuity-based pathway analysis was applied to identify upstream regulators and pathways specific to LESCs. ELISA
and flow cytometry were used to measure secreted and surface expressed proteins, respectively. More than 2 fold
increase and decrease in expression could be found in 1830 genes between the two cell types. A number of molecules
functioning in cellular movement (381), proliferation (567), development (552), death and survival (520), and cell-to-cell
signaling (290) were detected having top biological functions in LESCs and several of these were confirmed by flow
cytometric surface protein analysis. Custom-selected gene groups related to stemness, differentiation, cell adhesion,
cytokines and growth factors as well as angiogenesis could be analyzed. The results show that LESCs play a key role
not only in epithelial differentiation and tissue repair, but also in controlling angiogenesis and extracellular matrix
integrity. Some pro-inflammatory cytokines were found to be important in stemness-, differentiation- and
angiogenesis-related biological functions: IL-6 and IL-8 participated in most of these biological pathways as
validated by their secretion from LESC cultures.
Conclusions: The gene and molecular pathways may provide a more specific understanding of the signaling
molecules associated with LESCs, therefore, help better identify and use these cells in the treatment of ocular
surface diseases.
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The cornea serves mainly a protective and refractive func-
tion, being found on the outermost surface of the eye. It is
a highly transparent and strong tissue, separated from the
surrounding conjunctiva by a transitional zone - the lim-
bus. During eye development, the cornea is the last part of
the eye to be formed. It consists of a stratified epithelium
at the surface, stroma in the middle - populated by kerato-
cytes and fibroblast-like cells, and an inner layer of endo-
thelial cells, each separated by a Bowman’s and Descemet’s
membrane, respectively.
The human central corneal epithelial cells (CECs) are
derived and replaced continuously from the limbal epithe-
lial stem cells (LESC). The later can undergo asymmetric
division and give rise to transient amplifying cells (TACs),
which can then differentiate into mature CECs that lose
their ability to proliferate [1,2]. Animal studies have shown
that CECs arise from approximately 100 progenitor cells,
which means the frequency of LESCs is extremely low [3].
In humans, the LESCs have been found in the limbal epi-
thelial crypts - special niches at the peripheral edge of the
cornea [4-6]. Only six such crypts have been identified in
the limbus, further strengthened by findings from animals
[4]. The crypts provide a concentrated and safe place for
harboring LESCs, and also, a rich vascular supply with
growth factors and metabolites for their sustained persist-
ence [1,7-10]. LESCs play a key role not only in epithelial
differentiation, but also in wound healing, tissue regener-
ation and maintenance of a balanced immunological state
in the cornea [11].
Injuries - traumatic, chemical or iatrogenic, or diseases
of the LESCs, either inborn or acquired, can all lead to
partial or total LESC deficiency (LESCD) or corneal neo-
vascularization accompanied by inflammation. Full pene-
trating keratoplasty is not anymore the mainstay of
treatment for LESCDs, while autologous limbal graft
transplantation from a healthy donor eye, if available, does
not provide a guarantee for the functionality of the graft
itself. Isolation and ex vivo expansion of autologous or
homologous LESCs in human-like conditions has only
been described in detail in the last couple of years [12].
We recently published a method for cultivating and char-
acterizing LESCs grown on lens capsule in a medium con-
taining human serum as the only growth supplement [13].
The benefit of our method is not only the use of animal
material-free culturing conditions, but also, the ability to
investigate the phenotype and the genotype of the out-
growing cells, which can further help identify new putative
LESC markers.
In the present study, we compare the gene expression
patterns of ex vivo cultured human LESCs to differenti-
ated CECs with a main focus on markers for stemness and
proliferation, epithelial differentiation, tissue development
and growth, immunological and angiogenic factors. Inaddition, we propose a way to identify and possibly con-
centrate these stem cells found at low density from the
heterogeneous cell populations found in the cornea for fu-
ture use in clinical transplantation.
Methods
Ethics statement
All tissue collection complied with the guidelines of the
Helsinki Declaration and was approved by the Regional
Ethical Committee (DEOEC RKEB/IKEB 3094/2010).
Limbal tissue collection was done within 12 hours of bio-
logic death from cadavers only and Hungary follows the
EU Member States’ Directive 2004/23/EC on presumed
consent practice for tissue collection [14].
Isolation and cultivation of LESCs and CECs
In brief, after a thorough eye wash with 5% povidone iodine
(Betadine; Egis Pharmaceuticals PLC, Budapest Hungary),
the conjunctiva was incised and separated from the limbal
junction; consequently, a 2 × 1 mm rectangular-shaped
limbal graft was dissected away and towards the cornea,
respectively, at the 12 o’clock position. The depth of the
graft was kept superficial or within the epithelial layer;
multiple grafts were collected from a single eye and tested
for growth potential. The graft dissection was performed
using a lamellar knife placed tangential to the surface be-
ing cut. LESCs were cultured in a high-glucose Dulbecco-
modified Eagle’s medium (DMEM-HG, Sigma-Aldrich,
Budapest, Hungary) supplemented with 20% v/v human
AB serum, 200 mM/mL L-glutamine, 10,000 U/mL
penicillin- 10 mg/mL streptomycin (all from Sigma-
Aldrich) at 37°C, 5% CO2 in 1.91 cm
2 tissue culture
plates, while the medium was changed every alternate
day. The growth of the cells was monitored under phase
contrast microscope regularly. Only grafts which had
cell outgrowth within 24 hours were processed further
to decrease the chance of fibroblast contamination and
maintained in culture up to 14 days when they reached
95-100% confluence. Differentiated CECs were scraped
from the central part of the cornea of cadavers and were
used as a positive control. To avoid contamination of
one or the other cell type during isolation, different do-
nors were used for each isolation carried out.
Microarray and data analysis
Affymetrix GeneChip Human Gene 1.0 ST Arrays
(Affymetrix, Santa Clara, CA, USA) were used for the
microarray analysis. The array contained more than 28,000
gene transcripts. For the whole genome gene expression
analysis 150 ng of total RNA was subjected to Ambion
WT Expression Kit (Ambion, Life Technologies, Carlsbad,
CA, USA) and GeneChip WT Terminal Labeling Kit
(Affymetrix) according to the manufacturers’ protocols.
After washing, the arrays were stained using the FS-450
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tected by Hewlett Packard Gene Array Scanner 3000 7G
(Hewlett Packard, Palo Alto, CA, USA). The scanned im-
ages were processed using GeneChip Command Console
Software (AGCC) (Affymetrix) and the CEL files were
imported into Partek Genomics Suite software (Partek,
Inc. MO, USA). Robust microarray analysis (RMA) was
applied for normalization. Gene transcripts with a max-
imal signal values less than 32 across all arrays were re-
moved to filter for low and non-expressed genes, reducing
the number of gene transcripts to 23190. Differentially
expressed genes between groups were identified using
one-way ANOVA analysis in Partek Genomics Suite Soft-
ware. Clustering analysis was made using the same name
module in a Partek Genomics Suite Software.
Pathway analysis
To identify the relationships between selected genes, the
Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
Redwood City, CA) was used. Excel datasheets containing
gene IDs with the assigned gene expression values were
uploaded into the program. The Ingenuity Pathways
Knowledge Base (IPKB) provided all known functions and
interactions which were published in the literature.
ANOVA was used to calculate a p-value to determine the
probability that each biologic function or canonical path-
way assigned to the data set was due to chance alone. For
the representation of the relationships between the genes,
the ‘Pathway Designer’ tool of the IPA software was used.
Measurement of cytokine concentrations by ELISA
LESCs growing out of the limbal grafts were trypsinized
(0.025% trypsin-EDTA (PAA, Pasching, Austria, 5 mi-
nutes, 37°C) and seeded onto 24-well plates at a 5×104
cell/mL density. Cells were cultured for 9 to 13 days. At
the end of the culturing period, the supernatants were
harvested and kept at −20°C until further measurement.
BD OptEIA ELISA (BD Pharmingen, San Diego, CA,
USA) assay kits were used following the supplier’s in-
struction to measure the concentration of secreted IL-6
and IL-8 cytokines. Each experiment was performed at
least three times and each sample was tested in triplicates.
Statistically significant differences were determined by
paired student’s t test.
Transmission electron microscopy
Human corneal tissue procurement and use were con-
ducted in accordance with local regulations and approved
by the Research Ethics Committee of King Saud Univer-
sity. Unless specified otherwise, reagents were obtained
from TAAB Laboratories Equipment Ltd (Aldermaston,
UK). Pieces of LESCs grown on lens capsules were fixed
in freshly prepared 4% paraformaldehyde in 0.1 M
phosphate for 2 h at 4°C. Tissues were processed atlow temperatures and were embedded in LR White
resin (Sigma-Aldrich) at −20°C for 48 h under ultravio-
let light. Ultrathin sections were collected on 200 mesh
formvar-coated carbon nickel grids and examined in a
Jeol 1400 transmission electron microscope (Jeol Ltd,
Tokyo, Japan).Surface protein level analysis by flow cytometry
Fluorescein isothiocyanate (FITC), phycoerythrin (PE)
and allophycocyanin (APC) conjugated antibodies were
used for multicolour flow cytometric analysis to measure
the selected surface protein expression on isolated LESCs
and differentiated CECs. Antibodies against CD29/In-
tegrin β1, CD44/HCAM, CD45, CD54/ICAM1, CD73,
CD90/Thy-1, CD117/c-kit and CD146/MCAM markers
were used in a concentration specified by the manufac-
turer’s protocol (all antibodies were obtained from Bio-
legend, San Diego, CA, USA). All samples were labeled
for 30 minutes on ice, then measured by FACSCalibur
flow cytometer (BD Biosciences Immunocytometry Sys-
tems, San Jose, CA, USA) and the data were analyzed
using FlowJo (TreeStar, Ashland, OR, USA), software.
The results were expressed as means of positive cells (%) ±
SD. Statistically significant difference between the two groups
(LESC vs. CECS) was determined with paired student-t
test and a value of p < 0.05 was considered significant.Results
Gene array and IPA analysis
A microarray based transcriptional profiling was used to
compare LESCs to differentiated CECs. The intensity
profiles of the log2 transformed signal values of the
28869 transcripts were obtained, out of which 955 and
875 transcripts had a more than 2 fold change (FC) in-
crease and decrease in expression between the two cell
types, respectively (n = 3, p < 0.01). Table 1 summarizes
the most affected signaling pathways identified by the
IPA software based on the significant expression of
genes in the LESCs. The top canonical pathways in-
cluded genes involved in hepatic fibrosis, angiogenesis
inhibition by thrombospondin 1 (TSP-1), retinoic acid re-
ceptor (RAR) activation, antigen presentation and axonal
guidance signaling. Some of the signaling pathways were
also related to diseases or toxicological pathways such as
induction of reactive metabolites, renal ischemia and renal
proliferation. IPA could determine the biological functions
and diseases from the significantly changed expression
levels of groups of genes: 733 molecules were found to be
involved in cancer development, 567 in cellular growth
and proliferation, 552 in cellular development, 520 in cell
death and survival and 402 in gastrointestinal diseases.
Only a small number of molecules related to visual system
development and function (98), and 5 involved in increased
Table 1 The most significantly affected canonical pathways found in LESCs
Ingenuity canonical pathways -Log(B-H-P-value) Ratio
Top canonical pathways Hepatic fibrosis/hepatic stellate cell activation 8.36E-05 32/142 (0.225)
Inhibition of angiogenesis by TSP1 2.22E-04 12/34 (0.353)
RAR activation 5.01E-04 35/179 (0.196)
Antigen presentation pathway 1.25E-03 11/40 (0.275)
Axonal guidance signaling 1.31E-03 65/432 (0.15)
Top tox (toxicological) pathways Hepatic fibrosis 4.25E-06 27/93 (0.29)
Glutathione depletion - cyp induction and reactive metabolites 6.6E-05 7/12 (0.583)
Liver proliferation 1.5E-04 39/189 (0.206)
Persistent renal ischemia-Reperfusion injury (mouse) 4.41E-04 10/30 (0.333)
Increases renal proliferation 4.54E-04 24/101 (0.238)
IPA software was used to calculate the canonical pathways from the gene expression profile of LESCs grown on lens capsule.
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see Table 2).
Customized gene array data – upstream regulators
We selected 257 upstream regulators that were expressed
significantly and differentially in LESCs that were also re-
lated to our groups of interest (stemness and proliferation,
differentiation, cell adhesion, cytokines and growth factors
and angiogenesis). Their biological functions were exten-
sively related to physiological maintenance of LESCs,
while the molecules involved in these processes showed
significant inter-donor differences. Figure 1 shows the
heatmap and the functional clustering of the 257 up-
stream regulators selected on the basis of their high or
low FC or previously documented relation to LESCs. The
cluster analysis demonstrated a clear distinction between
the LESCs and our control CECs. The genes that were
mostly affected were involved in ion-, nucleotide- or
protein binding, protein secretion as well as receptor
or enzyme activities. Table 3 shows the top 20 up- or
down-regulated genes within these gene groups.
Customized gene networks – upstream regulators
Stemness and proliferation
As seen in Figure 2, out of the 257 upstream regulators,
122 were related to stemness and, in particular, mesen-
chymal stem cells (MSCs). The expression pattern also
demonstrated a clear difference between the LESCs and
the CECs (Figure 2A). These genes coded for transcrip-
tion factors, surface molecules, cytokines and growth
factors, all playing a key role in the maintenance of mul-
tipotency, proliferation capacity of hematopoietic and/or
MSCs (Figure 2B). Up- and down- regulation was found
in 66 and 56 genes, respectively, and within the custom
selected gene cluster, the 10 highest upstream regulators
were: CCNA1 (27.199 fold), IL1B (24.948), GDF15
(16.924), ICAM1 (13.681), TGFB (16.745) SOX9 (4.859
fold) VIM (4.368), NT5E (4.009) TGFBR2 (3.772) andBMP6 (3.494), while the 10 most down-regulated were:
BMP7 (−6.436 fold), LEF1 (−4.441), GJA1 (−3.94), KAT2B
(−3.829), KLF4 (−3.041), EGF (−2.563) FOXN1 (−2.11),
SOX6 (−1.984), GDF9 (−1.865) and HSPA9 (−1.838). The
expression of these selected genes strengthen our previous
findings that the ex vivo cultured LESCs show great simi-
larity to MSCs regarding their surface marker profile and
the extracellular matrix (ECM) production ability [13].
The present comparison is rather focused on the differ-
ences between LESCs and differentiated CECs in their
transcriptional factor patterns, making the LESCs more
progenitor-like, yet with a limited multipotency potential
as compared to other stem cells, including bone marrow-
derived MSCs (bmMSCs). As expected, our data show
that LESCs have a higher proliferation potential and
stemness-related gene expression than differentiated CECs.
The SRY related HMG-box family members SOX9 and
SOX6, both involved in chondrogenesis and prolifera-
tion, were down-regulated in the LESCs. Flow cytomet-
ric surface protein level analysis found a significantly
higher number of positive cells for ICAM1 in CECs
(56.19 ± 12.46%) than in LESCs (4.37 ± 7.63%) (p = 0.0001)
(Additional file 1: Figure S1). No difference could be
found in the well-known MSC surface markers, such as
CD90 (8.75 ± 19.56% in LESCs and 1.77 ± 3.54% in
CECs, respectively (p = 0.4748)) and CD73 (89.86 ±
6.15% in LECSs and 76.93 ± 17.43% in CECs, respect-
ively, (p = 0.2374); data shown are Mean ± SD), while
more cells expressed the stem cell factor receptor
CD117/c-kit in the LESCs (19.87 ± 24.92%) compared to
CECs (0 ± 0%) at a protein level, however, this difference
was not statistically significant (p = 0.1491) due to a
high inter-donor variance (Additional file 1: Figure S1).
Differentiation
Our previous phenotype analysis of LESCs showed the
heterogeneity of this population [13], so we analyzed 42
genes related to terminal and epithelial differentiation.
Table 2 Top biological and toxicological functions
Function Name p value Molecules
Diseases and disorders Cancer 5.96E-27 - 1.23E-03 733
Reproductive system disease 1.61E-16 - 1.19E-03 344
Dermatological diseases and conditions 3.42E-16 - 1.15E-03 282
Gastrointestinal disease 4.31E-13 - 8.26E-04 402
Endocrine system disorders 2.65E-10 - 7.46E-04 257
Molecular and cellular functions Cellular movement 5.90E-18 - 1.43E-03 381
Cellular growth and proliferation 1.31E-10 - 1.12E-03 567
Cellular development 3.26E-09 - 1.07E-03 552
Cell-to-cell signaling and interaction 8.23E-09 - 1.48E-03 290
Cell death and survival 1.04E-08 - 1.48E-03 520
Physiological system development and function Cardiovascular system development and function 9.52E-10 - 1.23E-03 271
Tumor morphology 6.48E-09 - 9.47E-04 140
Organismal development 9.59E-09 - 1.48E-03 371
Visual system development and function 1.34E-07 - 1.48E-03 98
Tissue development 2.59E-07 - 1.48E-03 350
Clinical chemistry and hematology Decreased levels of albumin 1.63E-03 - 3.94E-01 6
Increased levels of alkaline phosphatase 2.79E-03 - 1.18E-01 16
Increased levels of creatinine 8.01E-03 - 8.01E-03 8
Increased levels of potassium 1.48E-02 - 5.41E-01 7
Increased levels of albumin 1.09E-01 - 2.21E-01 5
Cardiotoxicity Cardiac stenosis 6.92E-04 - 3.13E-01 15
Congenital heart anomaly 3.64E-03 - 5.28E-01 23
Cardiac arteriopathy 4.20E-03 - 6.33E-01 42
Pulmonary hypertension 5.95E-03 - 1.18E-01 11
Cardiac hypertrophy 8.04E-03 - 1.00E00 51
Hepatotoxicity Liver proliferation 2.37E-04 - 3.13E-01 39
Liver cholestasis 6.93E-04 - 5.84E-01 22
Liver cirrhosis 7.33E-04 - 2.21E-01 31
Liver damage 8.26E-04 - 2.21E-01 33
Liver hyperplasia/hyperproliferation 8.39E-03 - 5.03E-01 80
Nephrotoxicity Renal proliferation 6.16E-06 - 2.21E-01 38
Renal damage 7.17E-04 - 5.03E-01 37
Renal tubule injury 7.17E-04 - 2.21E-01 24
Renal necrosis/cell death 1.84E-03 - 1.00E00 52
Renal inflammation 8.70E-03 - 1.00E00 34
The most affected pathways related to known biological and toxicological functions in LESCs as determined by the IPA software.
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the expressed genes show a clear segregation of the LESCs
from the differentiated CECs (Figure 3A). Among them,
growth factors, cytokines, adhesion molecules, transcrip-
tion regulators and enzymes can be found (Figure 3B).
Transcriptional regulators such as FOXG1 (−1.165),
FOXD3 (−1.1), MYOD1 and OSGIN1 (−1.109) were all
down-regulated in contrast to the FOXA1 and PMEL
up-regulation (Figure 3C). The pericellular matrixproteoglycan decorin coding gene DCN (−5.066) was
found to be down-regulated in LESCs. Within the collec-
tion of cytokines and growth factors which play a role in
epithelial differentiation, BMP7 (−6.436 fold), FGF1
(−2.96), FGF7 (−1.473), IL18 (−1.152) and IGF2 (−1.126)
were down-, while IL1B (24.948), INHBA (21.815), IL1A
(7.853), TGFB1 (6.745), EREG (3.836), BMP6 (3.494) and
DKK1 (2.88) were up-regulated (Figure 3D). At a protein
level, CD146/MCAM, a key player in MSCs differentiation,
Figure 1 (See legend on next page.)
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Figure 1 Heatmap of the differentially expressed genes in LESCs compared to CECs. Heatmap of the transcripts and functional clustering
of 257 genes expressed significantly different in LESCs and CECs, and related to stemness, epithelial differentiation, tissue organization and
angiogenesis. Red and blue colors indicate high and low expression, respectively. The cluster analysis and dendrogram show the difference
between the two cell types (A). Distribution of the 257 significantly differentially expressed genes by molecule type as defined by IPA (B).
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0%) compared to LESCs (82.40 ± 14.60%, p = 0.0002) (Add-
itional file 1: Figure S1). Presence of CK14 on LESCs
has been described by our group previously [13].
Cell adhesion
To further distinct the multipotent LESCs within the
heterogeneous population of epithelial cells, surface
markers including ECM-cell, cell-cell adhesion and cell
migration proteins were used as putative markers. The
upstream regulators of 54 genes coding for molecules in-
volved in cell adhesion were analyzed. (Figure 4A, E).
The first subgroup contained highly expressed transcrip-
tional factors and transmembrane receptors in the LESCs
(Figure 4C): TGFBI (6.745), AKT3 (11.843), CTGF (6.513),
MAP2K (12.088), SPP1 (2.077) and SRC (1.931). Six genes
including AKT1 (−1.026), NOV (−3.149), ROCK2 (−1.076),
PRKCA (−1.154), HRAS (−1.5) and PRKCB (−1.583) were
down-regulated. The next subgroup (Figure 4D), included
integrins, cell adhesion molecules (CAMs), proteolytic en-
zymes and matrix metalloproteases (MMPs) – all involved
in the ECM breakdown and tissue healing and remodel-
ing; the most up-regulated genes in this cluster were
MMP1 (13.875), MMP14 (1.836) and MMP9 (14.243),
while MMP3 was down-regulated (−1.105). The laminins,
which are important proteins in the basal membrane and
their coding genes such as LAMA1 (1.428), LAMA3
(3.289) and LAMC1 (1.724) were all up-regulated in the
LESCs. CAMs and tight junctions which are very import-
ant in cell-cell adhesion and tissue organization, such as
ICAM-1 (13.681), CAV1 (1.608) and CLDN7 (3.056) were
up-, while GJA1 (−3.94) was down- regulated. In particu-
lar, CDH1 (1.536), important in desmosomal junction for-
mation and stratified epithelium transformation was up-
regulated, and the desmosome formation between the
LESCs grown on lens capsule could be demonstrated
using transmission electron microscopy (Figure 4B).
Altogether, the expression of 11 integrin-coding genes was
different between the LESCs and the differentiated CECs -
8 out of them were up-, while 3 were down- regulated.
Surface protein level analysis found no difference between
LESCs and CECs in the expression of CD29/Integrin β1
(97.01 ± 1.87% and 78.28 ± 15.84%, respectively), and
CD44/HCAM (16.55 ± 23.21% and 19.83 ± 21.55%, re-
spectively) expression. The percentage of CD47 positive
cells, which plays a role in cell viability and immunoreg-
ulation, was significantly higher in LESCs (98.98 ±
0.57%) compared to CECs (25.9 ± 27.44%) (p = 0.0039),showing higher viability and inhibition of phagocytosis
in the LESCs (Additional file 1: Figure S1).
Cytokines and growth factors
Cytokines and growth factors have an important func-
tion in cell-cell communication and can affect cell func-
tion, differentiation and immunogenicity (Figure 5A).
IL1B was the most up-regulated gene (24.948 fold),
followed by CXCL10 (15.171), IL1A (7.853), IL8 (5.849),
EDN1 (5.504), IFNE (4.601), IL6 (2.57), SPP1 (2.077) and
CCL5 (1.973). Although most of the up-regulated genes
were related to pro-inflammatory cytokines, some mem-
bers with similar pro-inflammatory properties, but from
other cytokine families, were down-regulated: IL17
(−1.129), the IL-1 superfamily members IL18 (−1.152)
and IL36RN (−1.059). Human EDA (−1.113) which be-
longs to the TNF family was within the most down-
regulated genes, while the top down-regulated gene was
FAM3B (−3.900) (Figure 5B). Next, we filtered out the
entire dataset for growth factors, all being important for
maintaining multipotency and differentiation of progeni-
tor or stem cells (Figure 5C). The most up-regulated
genes were members of the TGF beta (TGFβ) superfam-
ily: INHBA (21.815 fold), GDF15 (16.924), TGFB1
(6.745) and BMP6 (3.494). Epiregulin and amphiregulin,
members of the epidermal growth factor (EGF) family,
were the top up-regulated genes: EREG (3.836) and
AREG (4.047), as well as connective tissue growth factor
CTGF (6.513). The down-regulated genes included other
TGFβ superfamily members: BMP7 (−6.436) and GDF9
(−1.865). Acidic fibroblast growth factor, FGF1 (−2.96)
and FGF7 (−1.473) were also down-regulated, as well as
NOV-like CTGF- member of the CCN protein family:
nephroblastoma overexpressed/NOV (−3.149). Similarly,
EGF gene expression responsible for regulation of cell
division and proliferation was down-regulated −2.563
fold.
Angiogenesis
48 molecules were detected in the dataset which may
have a role in pathological angiogenesis in the cornea
(Figure 6A). This set contained transcription factors, en-
zymes and cytokines including angiogenic growth factors
as well (Figure 6B). The fibronectin gene (FN1), which is
important in new vessel sprout formation, had the highest
up-regulation (74.934), followed by SERPINE1 (18.854)
and MMP9 (14.243). The coagulation factor III (thrombo-
plastin) gene F3 (7.054) was also highly expressed in the
Table 3 Top 20 up- and down-regulated custom selected genes in LESC
Symbol Entrez gene name Fold
change
Activation
z-score
p-value of
overlap
Molecule type
Fold change up-regulated
FN1 Fibronectin 1 74.934 2.979 8.37E-05 Enzyme
CCNA1 Cyclin A1 27.199 3.42E-02 Other
IL1B Interleukin 1, beta 24.948 4.924 8.09E-15 Cytokine
INHBA Inhibin, beta A 21.815 1.352 2.27E-04 Growth factor
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1
18.854 −0.927 1.40E-02 Other
GDF15 Growth differentiation factor 15 16.924 1.999 2.63E-02 Growth factor
PTHLH Parathyroid hormone-like hormone 16.2 1.972 8.72E-03 Other
OSMR Oncostatin M receptor 15.366 1.982 1.83E-02 Transmembrane
receptor
CXCL10 Chemokine (C-X-C motif) ligand 10 15.171 0.911 2.31E-02 Cytokine
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa type IV collagenase) 14.243 0.689 1.72E-02 Peptidase
IL1R1 interleukin 1 receptor, type I 13.972 2.603 5.76E-03 Transmembrane
receptor
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 13.875 1.188 4.01E-03 Peptidase
ICAM1 Intercellular adhesion molecule 1 13.681 2.961 1.36E-03 Transmembrane
receptor
ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 13.455 2.411 1.46E-02 Other
SH3KBP1 SH3-domain kinase binding protein 1 12.752 4.98E-02 Other
AKT3 V-akt murine thymoma viral oncogene homolog 3 (protein kinase B,
gamma)
11.843 4.76E-02 Kinase
LOXL2 Lysyl oxidase-like 2 11.734 1.992 1.88E-03 Enzyme
CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5 10.588 1.23E-02 Other
SLPI Secretory leukocyte peptidase inhibitor 8.53 −2.433 1.06E-02 Other
PDZK1IP1 PDZK1 interacting protein 1 8.485 1.23E-02 Other
Fold change down-regulated
CRTAC1 - Cartilage acidic protein 1 −72.277
LPA Lipoprotein, Lp(a) −11,623 4.98E-02 Other
ETV1 Ets variant gene 1 −7,444 1.969 1.83E-02 Transcription regulator
EDNRB Endothelin receptor type B −7,25 3.38E-02 G-protein coupled
receptor
BMP7 Bone morphogenetic protein 7 −6,436 0.733 1.17E-04 Growth factor
NREP Neuronal regeneration related protein −5,823 −0.248 3.81E-03 Other
CFTR Cystic fibrosis transmembrane conductance regulator (ATP-binding
cassette sub-family C, member 7)
−5,766 −1.993 1.49E-01 Ion channel
DCN Decorin −5,066 0.172 6.04E-07 Other
RORA RAR-related orphan receptor alpha −4,781 −0.439 2.61E-03 Ligand-dependent
nuclear receptor
LEF1 Lymphoid enhancer binding factor 1 −4,441 −0.306 2.01E-02 Transcription regulator
BDKRB1 Bradykinin receptor B1 −4,1 −2.000 6.89E-04 G-protein coupled
receptor
GJA1 Gap junction protein, alpha 1 −3,94 −1.480 5.54E-04 Transporter
FAM3B Family with sequence similarity 3, member B −3,9 3.20E-08 Cytokine
P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 −3,885 1.15E-02 Ion channel
KAT2B K(lysine) acetyltransferase 2B −3,829 1.963 8.27E-02 Transcription regulator
ODC1 Ornithine decarboxylase, structural 1 −3,63 4.98E-02 Enzyme
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Table 3 Top 20 up- and down-regulated custom selected genes in LESC (Continued)
EPHX2 Epoxide hydrolase 2, cytoplasm −3,469 3.42E-02 Enzyme
MAT1A Methionine adenosyltransferase I, alpha −3,386 −0.215 1.82E-02 Enzyme
CTSL2 Cathepsin L2 −3,385 4.98E-02 Peptidase
DUSP1 Dual specificity phosphatase 1 −3,358 −1.881 6.12E-02 Phosphatase
NOV Nephroblastoma overexpressed −3,149 0.555 1.94E-02 Growth factor
The top 20 up and down regulated genes in LESCs as determined by the IPA software.
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(−2.521), TIMP1 (−1.658), FOXO4 (−1.213), TGFBR1
(−1.179) (Figure 6C). Certain cytokines and growth factors
which are also important in angiogenesis (Figure 6D) were
up-regulated in the LESCs: ILB1 (24.948), C-X-C motif
chemokine 10, CXCL10 (15.171), TGFB1 (6.745) and
VEGFA (2.742). In addition, IL-6 and IL-8, two very po-
tent angiogenic cytokines, were up-regulated in these cells:
IL-6 (2.57) and IL-8 (5.849), similar to EDN1 (5.504),
EREG (3.836) and BMP2 (2.686) up-regulation within this
cluster. Only four of the angiogenic cytokines were down-
regulated in the LESCs: acidic FGF - FGF1 (−2.96), IL17F
(−1.129),TGFB2 (−1.106) and KITLG (−1.015).
Discussion
Absence or removal of the LESC layer in animals can
cause defective corneal epithelialization, indicating the
essential importance of these cells in corneal surface
biology and regeneration [15,16]. In humans, besides in-
juries and diseases, dysfunction or LESC loss can lead to
LESCD; other causes, such as genetic diseases can cause
abnormal development of the anterior segment and the
limbus, while Steven Johnson syndrome, chronic limbitis
or ocular pemphigoid are inflammatory processes which
can lead to LESCD, similar to cytotherapy, radiation or
surgery in the limbal region [9,17]. Altogether, a plethora
of causes can lead to decreased transparency of the cor-
nea, inflammation and corneal neovascularization (key
features of LESCD), resulting in a serious and painful
disease with subsequent loss of vision [18]. The inflam-
matory processes and the angiogenesis very likely change
the environment, so that the small niche of stem cells
becomes non-functional [6,10,19]. Therefore, the treat-
ment of LESCD with ex vivo cultured and functional
LESCs is becoming widely accepted today [20]. Many
other types of cells, including embryonic stem cells,
bone-marrow and Wharton jelly-derived stem cells have
been attempted for LESCD treatment in animal models
with relatively good outcomes [17,21]. Most cell-based
therapies in the clinical practice, however, use limbal
epithelial cells cultured on 3 T3 mouse feeder fibroblast
supplemented with fetal calf serum [22]. The risk of
murine (animal) viral transmission during such proce-
dures is not yet known [23,24]. Although the limbalepithelial cells cultivated on mouse feeder cells can re-
place the wounded epithelial cells, the mechanism how
they make the local tissue more suitable for its own stem
cells to recover their stemness and differentiation poten-
tial has been unknown [17]. This seemingly “gold stand-
ard” cell therapy method would not be able to compete
with human animal material-free product that would be
ideal for clinical use. Furthermore, the overall success
rate of the above therapies has been reported to be 76%
[24], although, the right quantity of cells needed for re-
covery has not yet been reported. In stem cells based
therapies, the purity of the product (the percentage of
stem cells within the cell culture) is crucial for the out-
come [24-26]. LESCs lose their multipotency during epi-
thelial expansion and differentiation [27], therefore, it is
important to distinguish between LESCs, TAMs and
CECs within the cell culture used for therapy. In our cell
cultures, the SRY related HMG-box family member
SOX9 was up-regulated, while SOX6 expression was
down-regulated, indicating no chondrogenic differenti-
ation but high proliferative capacity of the LESCs. Fur-
thermore, S100A4 and A9 proteins have been found to
be potent markers of limbal epithelial crypt cells [28] -
in our LESCs,- the S100A4 was down-regulated indicat-
ing they are not crypt cells. Others have reported that
CXCL12, COL2A, ISL1, FOXA2, NCAM1, ACAN, GJB1
and MSX1 can be used as putative markers to identify
LESCs [29]. We could not confirm a difference in these
genes between the LESCs and the differentiated CECs,
with the exception of FOXA1 which was up-regulated
and GJA1 down-regulated (also known as negative marker
for LESCs [30]). Similarly, Wnt2, Wnt6, Wnt11 and
Wnt16b have been reported to be typically expressed in the
limbal region and to be important for the LESCs prolifer-
ation [31]. We could confirm that WNT1 and WNT5A
expression was up-, while WNT3A was down- regulated
in our LESCs, along the wider lines of the results men-
tioned above. Surface protein level analysis found higher
positivity for CD146/MCAM, CD47 and CD117/c-kit in
LESCs compared to CECs, showing a pattern typical for
stem cells and higher multipotency in the earlier cell
type (Additional file 1: Figure S1). This phenotype ana-
lysis further proved simply using classical MSC markers,
such as CD90/Thy-1 and CD73, it is not possible to dif-
ferentiate between the two cell types.
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Figure 2 Upstream regulators as determinants for stemness. Selected upstream regulator genes which are involved in the maintenance of
stemness, cell cycle and multipotency-related transcription factors (A), and growth factors, cytokines and corresponding receptors (B). The gene
characteristics of MSCs are highlighted as well.
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Figure 3 Expression of terminal differentiation related genes. Expression of transcription factors, transmembrane receptors, enzymes and
adhesion molecules (A). Subgroups of cytokines- and growth factor coding genes involved in epithelial differentiation of stem cells (B). Distribution of
the selected 42 upstream regulators by molecule type, such as transcriptional regulators (C) and growth factors and cytokines (D).
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Figure 4 (See legend on next page.)
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Figure 4 Differential changes in selected genes related to cell-cell junction, cell-to-cell and cell-to-extracellular matrix (ECM) adhesion.
Collection of significantly different expressions of transcription factors, kinases and transmembrane receptors related to cell-cell connection and
adhesion (A). CAMs, integrins and ECM receptors determine the tissue origin of LESCs (C and D). Molecule types of the selected 54 upstream
regulator in the two groups of cells (E). TEM pictures about LESCs on lens capsule shows the cell-cell junctions between the cells (B) (LC = Lens
capsule, A = Attachment between LC and cells; C1, ,, C2 and C3 - three cell-layer, L = translucent space, D = Desmosomes.
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modeling, a process which usually starts with ECM break-
down [32,33]. The latter is mediated by MMPs, which
were up-regulated in the LESCs and their pattern impli-
cates a preferred degradation of collagens to rebuild the
ECM [32]. Laminins and vitronectin are typically found in
the limbal basal membrane [34,35] and their genes were
up-regulated in our LESCs.
For attachment to new ECM proteins, integrins and
CAMs are also essential, the expression of which is typical
for the tissue of origin. Indeed, the integrin expression is
able to define the cell phenotype and seems to be useful in
classifying MSCs from various tissues besides the well-
known MSC markers we have reported before [13]. The
results of our gene array data analysis strengthen the fact
that LESCs cultured in medium containing human serum
as the only growth supplement can keep their integrin
and CAM pattern that relates them to their limbal tissue
phenotype. Surface protein level analysis found same ex-
pression levels of CD29/Integrinβ1 and CD44/HCAM in
the two cell types, while CD54/ICAM1 positivity was
higher in the CECs (Additional file 1: Figure S1).
Wound healing can often lead into angiogenesis, which
can have a very important and controllable pathological
role in the limbus [33,36-38]. Fibronectin is an important
ECM protein in expanding cells as well as angiogenesis,
mediating sprouting, de novo vessel formation and endo-
thelial progenitor/stem cells differentiation into endo-
thelial cells [39-41]. The two highest up-regulated gene
products found in our LESCs seem to have an opposite ef-
fect on the angiogenesis pathway: IL-1β can induce-, while
CXCL10 can inhibit the formation of new vessels [42-46].
Interestingly, human limbal epithelial progenitor cells
have been found to express CXCL10 [47] while its absence
could decrease the level of IL-6 in mice corneas [48]. The
expression of TGFB1 is very important in wound healing
and in inducing VEGF expression, which was also up-
regulated in the LESCs, capable of provoking angiogenesis
in the damaged tissue [49,50]. Endothelin-1 has many dir-
ect and indirect angiogenic effects upon the endothelial
cells and fibroblasts - it provokes the release of the pro-
angiogenic compounds like VEGF from endothelial cells
and stimulates the fibroblasts to produce pro-angiogenic
proteases [51,52]. Altogether, our results indicate that both
pro- and anti-angiogenic genes are expressed at the same
time or in a balanced way in LESCs, maintaining anavascular state in the normal cornea. Loss of this con-
trol can be initiated by either a decreased production of
anti-angiogenic molecules or increased production of
pro-angiogenic and inflammatory factors. Although trans-
plantation of LESCs has been known to suppress corneal
inflammation and angiogenesis, the molecular mechanism
how LESCs participate in the processes has not yet been
fully understood [9,17,36,53,54]. Limbal niche cells have
been found to have a differentiating ability towards angio-
genic progenitors and inhibition of endothelial differenti-
ation of LESCs [53].
IL-6 and IL-8 can be secreted by many cell types during
inflammation or differentiation. These cytokines play a role
in inflammation, angiogenesis and MSC differentiation-
related processes [55]. Their gene expressions were up-
regulated in LESCs: IL-6 (2.570) and IL-8 (5.849). Using
the IPA analysis, the IL-6 signaling pathways were further
confirmed of being present in our LESCs compared to
CECs, together with some other well-known pathways de-
scribed below (Additional file 2: Figure S2A). The first
such pathway or network affected is the IL-1β and TNFα
mediated release of IL-6 from activated cells. This signal-
ing is further mediated by NFκB and JNK (JUN, C-Fos)
transcriptional factors and can lead to IL-6 and IL-8 re-
lease in parallel to collagen type I production (COL1A1),
which is the major component of connective tissue. The
second network affected is the autocrine or IL-6-mediated-
IL-6-secretion through RAF1, MAP2K and ERK1/2. This
process needs to be initiated by the IL-6 receptor (IL6R),
however, the JAK-STAT pathway (STAT3) can also induce
release of angiogenic factors such as VEGF and activation
of SOX3. As shown before in our dataset, IL1B was highly
up-regulated with a 24.948 fold change hand-in-hand with
its receptor IL1R1 (13.972) and IL1A (7.853). Although a
subunit of the receptor for IL-6 coding gene was down-
regulated - IL6R (−2.640), a member of the type I cytokine
receptor family - oncostatin M receptor (OSMR), was
found to be highly up-regulated (15.366) in the LESCs.
This receptor can form heterodimers with gp130, which is
a signal transducer for IL6R. It can also provide an intra-
cellular signal through Janus kinases after ligand binding.
In addition, many other ligands can be associated with
gp130 (and the IL6 receptor as well) such as IL-11, ciliary
neurotrophic factor (CNTF), leukemia inhibitory factor
(LIF) and cardiotrophin 1 (CT-1). Activation of RAS and
MAPK signaling can then be connected to the IL-1β
Figure 5 Differences in the expression of the cytokines and growth factors coding genes. Heatmap of the transcripts of cytokines- and growth
factors- coded genes in LESCs and CECs (A). Selection of significantly and differentially expressed genes of cytokines (B); and differentiation and
growth factors (C). In comparison to CECs, the LESCs expressed 37 cytokine and 40 growth factor coding genes in a significantly different manner.
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Figure 6 Significantly expressed angiogenesis-related genes in LESCs. Angiogenesis is a complex process mediated by MMPs, proteolytic
enzymes and ECM proteins (A). Cytokines and growth factors are important players of angiogenesis with endothelial cell activation and EPC/stem
cell differentiation (B). Most of the angiogenic molecules belong to these molecule types (C and D).
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http://www.biomedcentral.com/1471-2164/14/900mediated pathway. In our dataset, SOCS3 was up-
regulated (1.397), while SOCS1 was down-regulated
(−1.120). Four MAPKs were slightly up-regulated in the
LESCs: MAP2K1 (2.088), MAPK1 (1.339), MAPK14
(1.011) and MAPK3 (1.163), while the members of the
NFκB pathway were down-regulated: NFKB1 (−1.178)
and NFKBIA (−1.193). CXCL10 with high amount of IL-
6 has been shown to induce migration of trophoblasts
through activation of the CXCR3 receptor [56]. Interest-
ingly, CXCL10 was among the highest up-regulated
genes (15.171) in the LESCs compared to CECs (Add-
itional file 2: Figure S2B).
The pathways in which IL-8 participates are in general
more complex than for other cytokines. IL-8 can be pro-
duced by any cell possessing toll-like receptors during in-
flammation, and it is one of the most known chemotactic
factors for neutrophils and activator of immune cells [57].
(Additional file 3: Figure S3A). In addition, IL-8 has been
described as potent pro-angiogenic cytokine especially in
the eye [58,59], although the molecular background of
such angiogenic processes has not been well described.
IL-8 can bind to G protein-coupled serpentine receptors
such as CXCR1 and CXCR2 and beside immunological
activation, it can induce rearrangement of cytoskeletal
proteins, increase the expression of VCAM and ICAM1,
and the migration as well as vessel formation of endothe-
lial cells and stem cell-like endothelial progenitor cells, in
parallel with increase in vascular permeability (Additional
file 3: Figure S3B).
Our gene expression data which indicate that IL-6 and
IL-8 participate in most of the networks or selected path-
ways analyzed correlate well with the measurements of
their secreted levels in the supernatants of the cultured
LESCs. The level of these cytokines was continuously high in
the culture supernatants at days 9 (5885.24 ± 685.6 pg/mL)
and 13 (6147.14 ± 530.21 pg/mL) with no significant dif-
ference at both time points (p = 0.14) (Additional file 4:
Figure S4). For comparison, the physiologic level of IL-6
in the tear fluid of human subjects is very low (2.4 pg/mL)
(data from our group under publication). IL-6 can partici-
pate in many stem cell-related processes and has been
found to be important in maintaining the needed niche
for LESCs and LESC-epithelial interaction [60]. In bone
marrow-derived stem cells, IL-6 is needed for immuno-
suppression, which effect of the LESCs has been described
with different possible mechanisms [11].
Overall, our gene selection and networks are somewhat
different from the well-known canonical pathways de-
scribed so far because they were generated de novo and
were based on our data and the already published net-
works from literature. It remains to be further investigated
and confirmed whether these pathways are reflected in
the same manner at protein level both ex vivo and in situ,
giving a possibility of finding a specific phenotype andgenotype profile for LESCs. These can clearly be beneficial
in treating ocular surface diseases and discovering innova-
tive therapies aided by the gene array technology.
Conclusion
The human eye as an organ possesses great potential for
regeneration and cell therapy, in particular, its corneal sur-
face which contains LESCs. Identifying molecular markers
and upstream regulators in the LESCs using genome-wide
microarray transcriptional profiling, as well as verification
of those at protein expression level can provide a better
identification and more specific understanding of the sig-
naling molecules associated with these cells, therefore,
better application ocular surface disease treatment. Over-
all, we found that the human LESCs play a crucial role in
cellular movement and adhesion, epithelial differentiation
and tissue repair, as well as angiogenesis and extracellular
matrix integrity.
Additional files
Additional file 1: Figure S1. Surface protein level analysis by FACS.
Positivity of the LECSs and CECs for CD73, CD90/Thy-1, CD117/c-kit,
CD146/MCAM stemness markers, CD29/Integrin β1, CD44/H-CAM cell
adhesion molecules and CD47 cell viability and immunoregulatory
marker, were determined by flow cytometry. CD45 was used as a
negative control in these cells (Data shown are Mean ± SD; p < 0.05 *,
p < 0.01 **, p < 0.001 ***; N = 6).
Additional file 2: Figure S2. Networks generated by IPA which are
related to the IL-6 signaling pathway. The colored genes appear in the
studied dataset, red colored genes are up-, while green colored genes
are down-regulated. The grey colored genes did not fit the cut off level.
(A). 44 upstream regulators of the IL-6 signaling pathway in LESCs when
grouped upon biological functions of a molecule type (B).
Additional file 3: Figure S3. Networks generated by IPA which are
related to the IL-8 mediated signaling pathway. IL-8 plays a key role in
innate immunity (A) and as pro-angiogenic cytokine (B).
Additional file 4: Figure S4. Secreted IL-6 and IL-8 levels in LESC cultures.
The levels of secreted IL-6 and IL-8 as measured by ELISA in the supernatants
of long term LESC cultures. (N = 21, p values were determined by
student’s T test).
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AREG: Amphiregulin; BMP2: Bone morphogenetic protein 2; BMP6: Bone
morphogenetic protein 6; BMP7: Bone morphogenetic protein 7; CAMs: Cell
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10/interferon gamma-induced protein 10; CXCL12: Chemokine (C-X-C motif)
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cytokine signaling 3; SOX3: SRY-related HMG-box 3; SOX6: Transcription factor
SOX-6; SOX9: SRY (sex determining region Y)-box 9; SPP1: Secreted
phosphoprotein 1; SRC: Proto-oncogene tyrosine-protein kinase; STAT: Signal
transducer and activator of transcription; STAT3: Signal transducer and activator
of transcription 3; TACs: Transient amplifying cells; TGFB: Transforming growth
factor, beta; TGFB1: Transforming growth factor beta 1; TGFB2: Transforming
growth factor-beta 2; TGFBI: Transforming growth factor, beta-induced;
TGFBR1: Transforming growth factor, beta receptor I/activin A receptor type
II-like kinase; TGFBR2: Transforming growth factor, beta receptor II;
THY-1: Thymocyte differentiation antigen 1; TIMP1: TIMP metallopeptidase
inhibitor 1; TNFα: Tumor necrosis factor-alpha; TSP-1: Thrombospondin 1;
VCAM: Vascular cell adhesion protein 1; VEGF: Vascular endothelial growth
factor; VEGFA: Vascular endothelial growth factor A; VIM: Vimentin;
WNT1: Proto-oncogene protein Wnt-1; WNT5A: Protein Wnt-5a.
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